Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1979 Jul;16(1):1–6. doi: 10.1128/aac.16.1.1

Comparative Pharmacokinetics of Cephalexin, Cefaclor, Cefadroxil, and CGP 9000

Hartmut Lode 1, Ralf Stahlmann 1, Peter Koeppe 1
PMCID: PMC352777  PMID: 475366

Abstract

In a randomized crossover study, the pharmacokinetics of three new cephalosporin antibiotics, cefaclor, cefadroxil, and CGP 9000, in comparison to cephalexin, were determined after oral administration, by capsules, of 1,000 mg on an empty stomach in 12 normal subjects. Serum concentrations were measured during a period of 8 h, and urine recovery was measured during 24 h. The significant parameters of bioavailability of an orally administered substance were determined. The maximal serum concentrations (ymax) for cephalexin, cefaclor, cefadroxil, and CGP 9000 (in milligrams per liter) were: 38.8 ± 8.1; 34.6 ± 7.8; 33.0 ± 5.4; and 23.3 ± 7.3, respectively. The areas under the curve (in hours × milligrams per liter) were: 93.0 ± 14.8; 74.5 ± 9.9; 70.1 ± 9.0; and 108.5 ± 18.4, respectively. In a further crossover study with six subjects, 1,000 mg of cephalexin and of cefadroxil were given during a standard breakfast. The ymax of cephalexin decreased to 23.1 ± 6.6 mg/liter, in contrast to cefadroxil, with an unchanged ymax of 32.7 ± 3.4 mg/liter.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barza M., Weinstein L. Penetration of antibiotics into fibrin loci in vivo. I. Comparison of penetration of ampicillin into fibrin clots, abscesses, and "interstitial fluid". J Infect Dis. 1974 Jan;129(1):59–65. doi: 10.1093/infdis/129.1.59. [DOI] [PubMed] [Google Scholar]
  2. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bergan T. Kinetics of tissue penetration. Are high plasma peak concentrations or sustained levels preferable for effective antibiotic therapy? Scand J Infect Dis Suppl. 1978;(14):36–46. [PubMed] [Google Scholar]
  4. Bill N. J., Washington J. A., 2nd Comparison of in vitro activity of cephalexin, cephradine, and cefaclor. Antimicrob Agents Chemother. 1977 Mar;11(3):470–474. doi: 10.1128/aac.11.3.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bloch R., Szwed J. J., Sloan R. S., Luft F. C. Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure. Antimicrob Agents Chemother. 1977 Dec;12(6):730–732. doi: 10.1128/aac.12.6.730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Foglesong M. A., Lamb J. W., Dietz J. V. Stability and blood level determinations of cefaclor, a new oral cephalosporin antibiotic. Antimicrob Agents Chemother. 1978 Jan;13(1):49–52. doi: 10.1128/aac.13.1.49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ginsburg C. M., McCracken G. H., Jr, Clahsen J. C., Thomas M. L. Clinical pharmacology of cefadroxil in infants and children. Antimicrob Agents Chemother. 1978 May;13(5):845–848. doi: 10.1128/aac.13.5.845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Griffith R. S., Black H. R. Cephalexin. Med Clin North Am. 1970 Sep;54(5):1229–1244. [PubMed] [Google Scholar]
  9. Hartstein A. I., Patrick K. E., Jones S. R., Miller M. J., Bryant R. E. Comparison of pharmacological and antimicrobial properties of cefadroxil and cephalexin. Antimicrob Agents Chemother. 1977 Jul;12(1):93–97. doi: 10.1128/aac.12.1.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hodges G. R., Liu C., Hinthorn D. R., Harms J. L., Dworzack D. L. Pharmacological evaluation of cefaclor in volunteers. Antimicrob Agents Chemother. 1978 Sep;14(3):454–456. doi: 10.1128/aac.14.3.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Korzeniowski O. M., Scheld W. M., Sande M. A. Comparative pharmacology of cefaclor and cephalexin. Antimicrob Agents Chemother. 1977 Aug;12(2):157–162. doi: 10.1128/aac.12.2.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lode H., Kemmerich B., Koeppe P. [Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin]. Antimicrob Agents Chemother. 1975 Oct;8(4):396–401. doi: 10.1128/aac.8.4.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McCracken G. H., Jr, Ginsburg C. M., Clahsen J. C., Thomas M. L. Pharmacokinetics of cefaclor in infants and children. J Antimicrob Chemother. 1978 Nov;4(6):515–521. doi: 10.1093/jac/4.6.515. [DOI] [PubMed] [Google Scholar]
  14. Meyers B. R., Hirschman S. Z., Wormser G., Gartenberg G., Srulevitch E. Pharmacologic studies with cefaclor, a new oral cephalosporin. J Clin Pharmacol. 1978 Apr;18(4):174–179. doi: 10.1002/j.1552-4604.1978.tb01590.x. [DOI] [PubMed] [Google Scholar]
  15. Neu H. C., Fu K. P. Cefaclor: in vitro spectrum of activity and beta-lactamase stability. Antimicrob Agents Chemother. 1978 Apr;13(4):584–588. doi: 10.1128/aac.13.4.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pfeffer M., Jackson A., Ximenes J., de Menezes J. P. Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephradine. Antimicrob Agents Chemother. 1977 Feb;11(2):331–338. doi: 10.1128/aac.11.2.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Santoro J., Agarwal B. N., Martinelli R., Wenger N., Levison M. E. Pharmacology of cefaclor in normal volunteers and patients with renal failure. Antimicrob Agents Chemother. 1978 Jun;13(6):951–954. doi: 10.1128/aac.13.6.951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Speight T. M., Brogden R. N., Avery G. S. Cephalexin: a review of its antibacterial, pharmacological and therapeutic properties. Drugs. 1972;3(1):9–78. doi: 10.2165/00003495-197203010-00002. [DOI] [PubMed] [Google Scholar]
  19. Spyker D. A., Thomas B. L., Sande M. A., Bolton W. K. Pharmacokinetics of cefaclor and cephalexin: dosage nomograms for impaired renal function. Antimicrob Agents Chemother. 1978 Aug;14(2):172–177. doi: 10.1128/aac.14.2.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. WEINSTEIN L., DAIKOS G. K., PERRIN T. S. Studies on the relationship of tissue fluid and blood levels of penicillin. J Lab Clin Med. 1951 Nov;38(5):712–718. [PubMed] [Google Scholar]
  21. Wagner J. G. An overview of the analysis and interpretation of bioavailability studies in man. Pharmacology. 1972;8(1):102–117. doi: 10.1159/000136328. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES